A. Clara-Sosa et al. / Tetrahedron 60 (2004) 12147–12152
12151
3.2. General procedure for the preparation of trans- and
cis-N-(thiobenzyl)hexahydrobenzoxazolidin-2-one, 6a–d
pressure. The aqueous phase was extracted with 3!25 mL
portions of dichloromethane, and the combined organic
phase was dried with sodium sulfate. The solvent was
removed under reduced pressure. The solid obtained from
6a,b (0.30 g) was purified by fractional recrystallization
from dichloromethane–petroleum ether (95:5) to yield the
major diastereoisomers 5a,b as white crystals. The solid
obtained from 6c,d (0.27 g) was purified by preparative
TLC on silica gel (hexanes–EtOAc, 67:33, as eluent) to
yield the major diastereoisomer 5c,d as white crystals.
To a solution of hexahydrobenzoxazolidin-2-ones 4a–d7
(0.2 g, 1.42 mmol) in THF (10 mL) was slowly added at
0 8C n-BuLi (0.98 mL, 1.56 mmol, 1.6 M in hexanes). The
resulting mixture was stirred for 30 min at 0 8C, after which
was cooled at K78 8C. The lithiated oxazolidinones 4-Li
were treated with commercially available (S)-benzyl
phenyl-methanethiosulfonate (0.48 g, 1.70 mmol) in THF
(2 mL). The resulting solution was stirred for 3 h, allowed to
warm to rt, quenched with saturated aqueous NH4Cl,
extracted with 3!25 mL portions of dichloromethane,
and the combined organic phases dried with sodium sulfate.
The solvent was then removed under reduced pressure. The
pale yellow solid obtained (0.36 g) was purified by column
chromatography on silica gel (petroleum ether–EtOAc,
50:50, as eluent) to yield 6a–d.
3.3.1. (4S,5S,RS)-trans-N-(Benzylsulfinyl)hexahydroben-
zoxazolidin-2-one, 5a. Mp 105–106 8C; 0.17 g (50% yield),
[a]2D0ZK30.6 (c 1.0, CHCl3); 1H NMR (CDCl3, 400 MHz)
dZ1.3–1.6 (m, 8H), 1.8–2.0 (m, 4H), 2.23 (m, 1H), 2.43 (m,
1H), 3.55 (dt, 1H, 3JZ3.6, 11.6 Hz), 3.96 (dt, 1H, 3JZ3.6,
11.2 Hz), 4.28 (dd, 2H, 2JZ13.0 Hz), 7.2–7.4 (m, 5H);
13C{1H} NMR (CDCl3, 100 MHz) dZ23.3, 23.7, 28.7,
29.4, 61.0, 62.0, 81.8, 128.9, 129.9, 130.2, 158.0; IR (film)
3061, 2962, 2922, 2858, 1755, 1732, 1454, 1392, 1302,
1217, 1163, 1136, 1099, 1032, 762, 698 cmK1; HRMS-
ESCm/z found 302.0828 [(MCNa)C; calcd 302.0827 for
C14H17NO3SCNaC].
3.2.1. trans-(4S,5S)-N-(Thiobenzyl)hexahydrobenzoxa-
zolidinone 6a. Mp 102–103 8C; 0.34 g (91% yield),
[a]2D0ZK100.1 (c 1.0, CHCl3); 1H NMR (CDCl3,
400 MHz) dZ0.90 (m, 2H), 1.30 (m, 2H), 1.75 (m, 3H),
2.09 (m, 1H), 2.48 (td, 3JZ3.8, 11.2 Hz, 1H), 3.61 (td, 3JZ
3
3
3.8, 11.2 Hz, 1H), 3.81 (d, JZ12.8 Hz, 1H), 4.19 (d, JZ
12.8 Hz, 1H), 7.32 (m, 5H); 13C{1H} NMR (CDCl3,
100 MHz) dZ23.3, 23.8, 27.5, 28.5, 41.5, 66.2, 82.4,
127.6, 128.6, 129.5, 136.3, 159.5; IR (film) 3865, 3741,
3618, 3564, 2993, 2361, 1767, 1651, 1512, 1458, 1381,
1242, 1057 cmK1; C14H17NO2S (263.36) calcd: 63.79% C,
6.45% H, 5.31% N; found: 63.63% C, 6.51% H, 5.34% N.
3.3.2. (4R,5R,SS)-trans-N-(Benzylsulfinyl)hexahydroben-
zoxazolidin-2-one, 5b. Mp 102–103 8C; 0.18 g (55% yield),
[a]D20ZC32.0 (c 0.9, CHCl3). H and 13C NMR spectra
1
identical with those for 5a.
3.3.3. (4S,5R,SS)-cis-N-(Benzylsulfinyl)hexahydroben-
zoxazolidin-2-one, 5c. Mp 98–99 8C; 0.15 g (46% yield),
[a]2D0ZC185.3 (c 1.0, CHCl3); 1H NMR (CDCl3,
400 MHz) dZ0.92 (m, 1H), 1.10 (m, 1H), 1.34 (m, 2H),
1.55 (m, 2H), 1.75 (m, 2H), 4.14 (c, 1H, 3JZ12.0, 6.4 Hz),
3.2.2. trans-(4R,5R)-N-(Thiobenzyl)hexahydrobenzoxa-
zolidinone 6b. Mp 104–105 8C; 0.35 g (92% yield),
1
[a]D20ZC98.1 (c 0.9, CHCl3). H and 13C NMR spectra
identical with those for 6a.
2
3
4.34 (d, 1H, JZ12.8 Hz), 4.44 (c, 1H, JZ11.6, 5.6 Hz),
2
4.90 (d, 1H, JZ12.8 Hz), 7.38 (m, 5H); 13C{1H} NMR
3.2.3. cis-(4R,5S)-N-(Thiobenzyl)hexahydrobenzoxazoli-
dinone 6d. Mp 50–51 8C; 0.34 g (90% yield),
[a]2D0ZC131.1 (c 1.0, CHCl3); 1H NMR (CDCl3,
400 MHz) dZ1.29 (m, 2H), 1.45 (m, 2H), 1.65 (m, 4H),
(CDCl3, 100 MHz) dZ19.1, 19.3, 26.9, 27.5, 55.5, 59.0,
75.0, 128.4, 128.7, 128.8, 129.8, 154.8; IR (film) 1755,
1217 cmK1; HRMS-ESCm/z found 302.0841 [(MCNa)C;
calcd 302.0827 for C14H17NO3SCNaC].
3
3
3.10 (c, JZ5.6, 12.1 Hz, 1H), 3.80 (d, JZ12.8 Hz, 1H),
3
3
4.15 (d, JZ12.4 Hz, 1H), 4.32 (c, JZ5.8, 12.1 Hz, 1H),
7.30 (m, 5H); 13C{1H} NMR (CDCl3, 100 MHz) dZ19.1,
19.6, 25.7, 26.8, 41.8, 58.2, 74.4, 127.6, 128.6, 129.4, 135.6,
159.1; IR (film) 3865, 3741, 3618, 2993, 1759, 1512, 1381,
1242, 1057 cmK1; HRMS-ESCm/z found 264.1068
[(MCH)C; calcd 264.1058 for C14H17NO2SCHC].
3.3.4. (4R,5S,RS)-cis-N-(Benzylsulfinyl)hexahydroben-
zoxazolidin-2-one, 5d. Mp 96–97 8C; 0.14 g (43% yield),
1
[a]D20ZK184.1 (c 1.0, CHCl3). H and 13C NMR spectra
identical with those for 5c.
3.4. Preparation of (SS) and (RS)-benzyl methyl
sulfoxides 8a,b
3.2.4. cis-(4S,5R)-N-(Thiobenzyl)hexahydrobenzoxazoli-
dinone 6c. Mp 50–51 8C; 0.34 g (90% yield),
1
[a]D20ZK128.1 (c 1.1, CHCl3). H and 13C NMR spectra
identical with those for 6d.
To a previously cooled solution at K78 8C of N-(benzyl-
sulfinyl) hexahydrobenzoxazolidin-2-one 5a–d (0.04 g,
0.143 mmol) in THF (10 mL) was added dropwise MeMgBr
(1.4 M, in toluene–THF 75:25, 0.20 mL, 0.28 mmol). The
reaction was quenched with saturated aqueous NH4Cl
(1 mL). The solvent was removed under reduced pressure,
extracted with 3!25 mL portions of ethyl acetate, and
the combined organic phase was dried with sodium sulfate.
The solvent was then removed under reduced pressure. The
product and the chiral auxiliary were purified by preparative
TLC (petroleum ether–EtOAc, 33:67, as eluent). The
recovered chiral auxiliary afforded 18 mg (90%).
3.3. General procedure for the preparation of trans- and
cis-N-(benzylsulfinyl)hexahydrobenzoxazolidin-2-one,
5a–d
To a solution of N-(thiobenzyl)hexahydrobenzoxazolidin-2-
one 6a–d (0.31 g, 1.2 mmol) in MeOH (12 mL) was added
NaIO4 (0.77 g, 3.7 mmol) in H2O (6 mL). The reaction
mixture was stirred for 42 h at rt. The white solid formed
was filtered, and the MeOH was removed under reduced